OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2017.7617 OL-0-0-7617 Articles Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer JeongYoung Ju 1 ParkSung Hwan 1 MunSung Hee 2 KwakSang Gyu 3 LeeSun-Jae 4 OhHoon Kyu 4 Department of Surgery, College of Medicine, Catholic University of Daegu, Daegu 705-718, Repulic of South Korea Department of Radiology, College of Medicine, Catholic University of Daegu, Daegu 705-718, Repulic of South Korea Department of Medical Statistics, College of Medicine, Catholic University of Daegu, Daegu 705-718, Repulic of South Korea Department of Pathology, College of Medicine, Catholic University of Daegu, Daegu 705-718, Repulic of South Korea Correspondence to: Professor Hoon Kyu Oh, Department of Pathology, College of Medicine, Catholic University of Daegu, 3056-6 Daemyoung-4-dong, Nam-gu, Daegu 705-718, Republic of Korea, E-mail: ap510@cu.ac.kr 02 2018 14 12 2017 15 2 2431 2440 25102016 03082017 Copyright © 2018, Spandidos Publications 2018

We hypothesized that lysyl oxidase (LOX) contributes to the formation of fibrotic focus (FF) in association with inflammation and serves a significant role in breast carcinogenesis. In the present study, the association between the expression of LOX family members and FF with regards to with inflammation was analyzed, and the prognostic significance of LOX and FF in breast cancer was investigated. Immunohistochemical staining for LOX, LOX-like protein (LOXL) 1, LOXL2 and LOXL3 was performed in primary breast cancer tissues. The status of FF within the tumor was assessed, including size and grade. Levels of inflammatory markers, intratumoral and peritumoral lymphocyte infiltration were also evaluated. The clinicopathological characteristics were evaluated from the medical records of patients. In the present study, the expression of LOX family members was not associated with the presence of FF. FF was identified to be associated with intratumoral and peritumoral inflammation, tumor stage, larger tumor size, lymph node metastasis, high histologic grade, and p53 expression. LOX and LOXL3 were associated with intratumoral, and peritumoral inflammation. Furthermore, LOXL1 was associated with intratumoral inflammation and interleukin-4. In addition, LOX was associated with cluster of differentiation 8+ T cells. LOXL3 was associated with expression of ER and PR, and molecular subtype. In the survival analysis, overall survival time was statistically significantly longer in the FF-negative compared with that in the FF-positive group. In conclusion, it was demonstrated that FF and the expression of LOX family members were associated with inflammation in breast cancer. FF was associated with poor prognostic markers of breast cancer. Further studies are required to clarify the mechanisms underlying the association between the LOX family, FF and inflammation in breast cancer.

 lysyl oxidase LOX fibrotic focus inflammation breast cancer Introduction

Carcinogenesis is a complex process forming a cancer and is determined by cellular, genetic and epigenetic changes. In recent years, various factors have been investigated to reveal the mechanism of carcinogenesis and especially tumor microenvironment has been recognized as an important factor in carcinogenesis. One of the main components of tumor microenvironment is the extracellular matrix (ECM) remodeling (1,2). The ECM is defined as a complex structure build by interacting extracellular molecules including proteoglycans, polysaccharides, fibronectin, laminin and fibers such as collagen and elastin. The ECM provides structural and mechanical support to cells and tissues (1). During carcinogenesis, the composition and the overall content of the ECM change and the ECM is progressively stiffened (3,4). ECM stiffness has been implicated to promote tumor progression (5) and is partially associated with lysyl oxidase (LOX)-mediated collagen cross-linking (2,5).

LOX is a copper-containing amine oxidase that catalyzes lysine-derived cross-links in collagen and elastin and stabilizes the ECM (6). For many years, LOX has been demonstrated that it has diverse functions including the ability regulating gene transcription, cell growth control, cell motility and migration and cell adhesions (7). LOX is encoded by the LOX gene located on chromosome 5 (5q23.3–31.2) and belongs to a copper dependent amine-oxidase family currently consisting of five members (LOX, LOX-like protein (LOXL) 1, LOXL2, LOXL3 and LOXL4) (6,8–11). Recent studies have shown that LOX family is related to tumor fibrosis, invasion and metastasis (10–13).

ECM stiffness is caused by collagen deposition and linearization and bundling of interstitial collagen (4) and LOX has a crucial role in stiffness-associated tumor progression (5,10,14). ECM remodeling including stiffness contributes to fibrotic changes in tumor (15), which is defined as fibrotic focus (FF). Since Hasebe et al (16) have proposed FF as an indicator of tumor aggressiveness in invasive breast cancer, many studies have shown the relationship between FF and the prognosis of breast cancer (17).

Inflammation has been also recognized as an important component of tumorigenesis, and it usually precedes fibrosis (18). Recently, it has been described that inflammation plays an important role in fibrosis as an inducer of epithelial-mesenchymal transition (EMT) in cancer (19). Also, it has been suggested that invasion and aggression of breast cancer correlates with ECM stiffening and immune cell infiltration (4).

Nevertheless, the mechanisms of LOX-mediated tumor progression in association with fibrosis and inflammation are not fully understood. In this study, we analyzed the association between the expression of the members of the LOX family and FF in relation with inflammation, and investigated the prognostic significance of the members of the LOX family and FF in human breast cancer.

 Materials and methods <sec> <title>Patients and materials

Patients with primary breast cancer who underwent surgery between January 2003 and December 2010 at the Daegu Catholic University Hospital (Daegu, Korea) were enrolled. Formalin-fixed and paraffin-embedded specimens from the patients were stained with hematoxylin and eosin (H&E) and histologically examined and reviewed by an experienced pathologist. The clinicopathologic characteristics were evaluated based on the pathologic reports and the medical records. Disease stage was assessed according to the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual for breast cancer. Molecular subtype of the breast cancer was classified according to the immunohistochemical findings for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 labeling index. The informed written consent was obtained from all patients for the use of their data. The ethics review of the study was waived from the Institutional Review Board at the Daegu Catholic University Hospital according to the deliberation criteria.

 Tissue microarray and immunohistochemistry

Representative paraffin blocks of invasive breast carcinomas were selected to prepare for tissue microarray (TMA) and TMA was constructed following the methods described in our previous study (20). TMA blocks were cut into 5 µm-thick sections and immunohistochemical staining was performed on the TMA sections using the Bond Polymer Intense Detection System (Leica Microsystems, Victoria, Australia) according to the manufacturer's instruction with minor modifications.

Immunohistochemical staining for the members of the LOX family were conducted using commercially available primary antibodies, LOX (1:200, ab31238; Abcam, Cambridge, MA, USA), LOXL1 (1:100, NBP1-82827; Novus Biologicals, Littleton, CO, USA), LOXL2 (1:100, NBP1-32954; Novus Biologicals) and LOXL3 (1:100, NBP1-85908; Novus Biologicals). The TMA sections were also immunostained for CD4 (RTU, clone 4B12; Leica Biosystems, Wetzlar, Germany), CD8 (1:200, clone C8/144B; Dako, Glostrup, Denmark), CD68 (1;200, clone PG-M1; Dako), ER (1:100, clone 6F11; Novocastra, Newcastle, UK), PR (1:100, clone 16; Novocastra), HER2 (1:250, A0485; Dako), Ki-67 (1:200, MM1-L; Novocastra), Bcl-2 (1:4, clone 124; Dako), p53 (1:200, BP53.12; Zymed, Carlsbad, CA, USA) and epidermal growth factor receptor (EGFR) (1:100, clone EGFR.25; Novocastra). The levels of LOX, LOXL1, LOXL2 and LOXL3 assessed semiquantitatively as: 0 (no staining); 1+ (minimal intensity, <10% of cells); 2+ (moderate, 10–49%); and 3+ (marked, ≥50%). The expression level 0 and 1 were designated as negative and 2 and 3 as positive. Fig. 1 shows representative microphotographs of immunohistochemical expression of LOX, LOXL1, LOXL2 and LOXL3. The number of cluster of differentiation (CD)4+ T cells, CD8+ T cells and CD68+ macrophages was evaluated under a microscopic and counted both in the stroma and the cancer cell nest. Intratumoral (within the tumor boundary) and peritumoral (at the edge of tumor boundary) lymphocyte infiltration was also assessed semiquantitatively as follows: 0 (no or scant lymphocytes); 1 (a few scattered lymphocytic infiltration); 2 (scattered lymphocytic aggregation); and 3 (diffuse and dense aggregation of lymphocytes), where 1, 2 and 3 are designated as positive and 0 is as negative.

FF was diagnosed when there was a scar-like area or radially expanding fibrous bands consist of the fibroblasts and collagen fibers within the tumor, and surrounded by a highly cellular zone of infiltrating carcinoma cells (17). Fig. 2 shows representative example of FF in H&E stained breast cancer specimen. The status of FF within the tumor was assessed including size and grade and a minimal dimension of 1 mm of a fibrosclerotic core was referred to as FF.

 RT-PCR

The levels of cytokines including tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-2, IL-4, IL-6, transforming growth factor (TGF)-β, interferon (IFN)-γ and nuclear factor (NF)-κB p50 were assessed by the levels of RNA transcripts in frozen tissue using RT-PCR. Total RNA was isolated from frozen breast cancer tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. Reverse transcription of total RNA was performed using a commercial kit (Superscript II RNase H-reverse transcriptase; Invitrogen; Thermo Fisher Scientific, Inc.). PCR amplification was performed with specific primers and the sequences of primers are presented in Table I. PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide staining.

 Statistical analysis

Statistical analyses were performed using SPSS software version 19.0 (SPSS, Inc., Chicago, IL, USA). Association between FF and LOX, LOXL1, LOXL2 and LOXL3 was analyzed using the Chi-square test. Association of FF with number of inflammatory cells was assessed using two sample t-test. Association of FF with the clinicopathologic characteristics was analyzed using two sample t-test and the Chi-square test. Binary logistic regression analysis was performed to assess the odds ratios (ORs) of the statistically significant factors in univariate analysis. Association of the members of the LOX family with number of inflammatory cells was assessed using two sample t-test. Association between the members of the LOX family with the clinicopathologic characteristics was analyzed using two sample t-test and the Chi-square test. Survival data were analyzed using Kaplan-Meier survival analysis. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Clinicopathologic characteristics of the patients

A total of 291 patients with invasive breast cancer were included in this study. The mean age of the patients was 52.63±11.01 years (range, 24–90 years). Clinicopathologic characteristics of the patients are shown in Table II. Among the patients, the most common histologic type of invasive cancer was invasive ductal carcinoma not otherwise specified (89.7%), and the remaining were infiltrating lobular carcinoma (n=7), papillary carcinoma (n=4), micropapillary carcinoma (n=2), mucinous carcinoma (n=4), tubular carcinoma (n=4), metaplastic carcinoma (n=3), medullary carcinoma (n=2), sarcoma (n=1), inflammatory carcinoma (n=1) and mixed type (n=2).

 Association between FF and LOX families

The percentage of positive FF was 37.5% and positive rate of LOX expression was 49.1% in primary breast cancer tissues. The expression of LOX, LOXL1, LOXL2 and LOXL3 was not associated with presence of FF (Table III).

 Association of FF with clinicopathologic features

By univariate analysis, FF was statistically significantly associated with stage II tumors (P<0.001), larger tumor size (P<0.001), lymph node metastasis (P<0.001), high histologic grade (P=0.001), p53 (P=0.018), intratumoral and peritumoral inflammation (P<0.001 and P<0.001, respectively) (Table IV). Multivariate analysis using covariate with P<0.2 in univariate analysis was performed to assess the independent association of FF with clinicopathologic features. We found a significant association between FF and tumor size, histologic grade, lymph node metastasis and p53 (Table V).

 Association of LOX families with clinicopathologic features

By univariate analysis, LOX was statistically significantly associated with intratumoral and peritumoral inflammation (P<0.001 and P<0.001, respectively) (Table VI). LOXL1 was statistically significantly associated with intratumoral inflammation (P=0.021). LOXL2 was also statistically significantly associated with intratumoral and peritumoral inflammation (P=0.004 and P=0.041, respectively). LOXL3 was significantly associated with positive expression of ER and PR (P<0.001 and P<0.001, respectively) and molecular subtype (P<0.001).

 Association of FF and LOX families with inflammatory markers

Immunohistochemical staining for CD4+ T cells, CD8+ T cells and CD68+ macrophages were performed in 77 patients who had undergone surgery from January 2008 to December 2010. The levels of RNA transcripts for TNF-α, IL-4 and NF-κB p50 were analyzed in frozen tumor tissues although the expression levels of RNA transcripts for IL-1, IL-2, IL-6, TGF-β and IFN-γ were too low to be analyzed. In subgroup analysis, LOX and CD8+ T cell showed significant correlation (P=0.030) and LOXL1 and IL-4 showed significant association (P=0.019) (Table VII).

 Association of FF and LOX family with patient outcomes

The median follow-up period was 72 months (range 1–147 months). Among 291 patients, 35 patients (12.0%) showed tumor recurrence and 26 patients died from breast cancer. The 5-year survival rate was 90.0%. Overall survival (OS) was statistically significantly longer in negative FF group than in positive FF group (P=0.026) (Fig. 3A). Disease free survival (DFS) was longer in negative FF group although there was no statistical significance (P=0.054) (Fig. 3B). There was no significant association between LOX family and patients outcomes.

 Discussion

Tumor fibrosis and inflammation have been increasingly recognized as important factors which influence tumor progression and metastasis. Recent studies have demonstrated that LOX is involved in creating fibrotic microenvironment and fibrosis-enhanced cancer metastasis (5,21,22). Nevertheless, the relationship between LOX, FF, inflammation and tumor progression in human breast cancer have yet to be fully elucidated. FF is distinguished from organ fibrosis by the characteristics such as irregular or storiform patterned arrangement of fibroblast and collagen fibers, which shows radially expanding fibrous bands surrounded by a highly cellular zone of infiltrating carcinoma cells, and the location in the center of the tumor (17). In this study, we aimed to investigate whether LOX contribute to the formation of FF, especially in association with inflammation. There was no direct correlation between the members of the LOX family and FF in this study. However, FF, LOX, LOXL1 and LOXL2 showed significant correlation with intratumoral inflammation and FF, LOX and LOXL2 also related to peritumoral inflammation. These results suggest that the members of the LOX family and FF interact in relation with inflammation in breast cancer. Although the mechanisms by which LOX mediates FF formation in tumor are not clarified, functions of the LOX family in association with fibrosis in the cardiovascular system are relatively clear (23). LOX has been shown to be up-regulated by cytokines including TGF-β, TNF-α and IL-6 (23). Also, it has been implicated that LOX-mediated collagen cross-linking is critical in ECM stiffness (2,5). Acerbi et al (4) have shown that both ECM stiffness and cellular TGF-β signaling correlated positively with immune cell infiltration in human breast cancer. Leight et al. have demonstrated that increased matrix stiffness regulates TGF-β signaling, a potent inducer of EMT in tumor cells (24). In recent years, it has been suggested that EMT contributes to increase the collagen producing fibroblasts (21) and fibroblasts form FF in fibrotic tissues (17). Taken together these results also support our hypothesis. As far as I know, this is the first study to investigate the relationship between the members of the LOX family and FF.

It is well documented that organ fibrosis is associated with chronic inflammatory diseases (18,19). A number of studies have suggested the role of inflammatory cells such as macrophage and T-lymphocytes in fibrotic tissue (18,25,26). Also, various inflammatory mediators including TGF-β, TNF-α, IL-4 and NF-κB have been demonstrated to regulate the inflammatory responses as well as the fibrotic signaling cascade (18,19). TNF-α is crucial for the induction of NF-κB (27), the major factor in the inflammatory response and activated NF-κB is known to contribute to organ fibrosis and cancer development (19,28,29). Furthermore, hypoxia in fibrosis and tumor microenvironment cooperates with inflammatory response in the induction of EMT process (19,30,31). Interestingly, hypoxia induces LOX expression in tumor cells (32) and contributes to promote fibrogenesis and tumor progression through the reinforcement of the EMT process (19,33). In this study, we analyzed the association between FF, the members of the LOX family and inflammatory response. Although the results did not show any association between FF and inflammatory markers, there was significant correlation between LOX and CD8+ T cell. CD8+ T cells are important for the adaptive immune responses and have antitumor effects through various mechanisms. One of the mechanisms, CD8+ T cells secret cytokines such as TNF-α and IFN-γ, and LOX is known to be up-regulated by cytokines including TNF-α (23). In this regards, CD8+ T cells may affect the expression of LOX. Also, our results showed significant association between LOXL1 and IL-4. IL-4 is a T-lymphocyte-associated cytokine that is involved in humoral and adaptive immunity (34). IL-4 has many biological effects and affects various cell types (34). Interestingly, IL-4 stimulates fibroblasts proliferation34 and LOXL1 is secreted by fibrogenic cells including fibroblasts (9). Although the mechanism of regulation of LOXL1 has not been fully elucidated, our results suggest that IL-4 may affect the expression of LOXL1.

In previous studies, FF has been reported to be associated with poor prognosis in breast cancer (17). Hasebe et al (35) have demonstrated that the presence of a FF was associated with larger tumor size, high histologic grade, lymph and blood vessel invasion, presence of lymph node metastases, pTNM stage and a shorter DFS and OS in survival analysis. In consistent with the results of previous studies, our results showed that the presence of a FF is associated with more aggressive characteristics of breast cancer. FF was statistically significantly associated with tumor stage, larger tumor size, lymph node metastasis, high histologic grade and p53. Also, OS and DFS were statistically significantly longer in negative FF group than in positive FF group in this study.

In recent years, diverse functions of LOX have been revealed, and LOX has emerged as therapeutic target in cancer therapy. Many pre-clinical studies have described that LOX promotes tumor progression and metastasis (5,13,36,37). In clinical studies, most of studies have also shown that LOX and LOXL expression correlated with a poor prognosis in cancer (13,14,38–40), although study methods were somewhat different from each other. In our study, however, LOX as well as LOXL1 and LOXL2 did not show clinical relevance except LOXL3. Nevertheless, our study describes for the first time that LOXL3 was significantly associated with positive expression of ER and PR and molecular subtype in breast cancer.

Limitations of the present study include the use of the paraffin-embedded tumor tissues in detecting FF and the members of the LOX family, but the fresh frozen tissue in analyzing inflammatory mediators. Tissue processing can cause genetic alterations and molecular changes in tissues (41), and the levels of mRNA transcripts or protein in the paraffin-embedded tissues can be different from those in fresh frozen tissue. Also, we employed immunohistochemical staining to assess the levels of the members of the LOX family, but this method is semiquantitative and less accurate than other objective methods such as quantitative fluorescence analysis or real-time quantitative PCR. Furthermore, we did not include control group such as normal or benign breast tissue. A comparative study between tumor tissue and control group may be necessary to clarify the role of LOX and FF in breast cancer.

In conclusion, our study showed that FF and LOX family are associated with inflammation in breast cancer, although there is no direct correlation between FF and the members of the LOX family. In consistent with the previous studies, our results showed that FF is associated with poor prognosis. And for the first time, we found that LOXL3 was significantly associated with positive expression of ER and PR and molecular subtype in breast cancer. Further studies are required to clarify the mechanisms relating to the LOX family, FF and inflammation in breast cancer.

 Acknowledgements

This study was supported by the grant of Research Institute of Medical Science, Catholic University of Daegu (2013).

 References PupaSMMénardSFortiSTagliabueENew insights into the role of extracellular matrix during tumor onset and progressionJ Cell Physiol192259267200210.1002/jcp.1014212124771 LeventalKRYuHKassLLakinsJNEgebladMErlerJTFongSFTCsiszarKGiacciaAWeningerWMatrix crosslinking forces tumor progression by enhancing integrin signalingCell139891906200910.1016/j.cell.2009.10.02719931152 GilkesDMSemenzaGLWirtzDHypoxia and the extracellular matrix: Drivers of tumour metastasisNat Rev Cancer14430439201410.1038/nrc372624827502 AcerbiICassereauLDeanIShiQAuAParkCChenYYLiphardtJHwangESWeaverVMHuman breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltrationIntegr Biol (Camb)711201134201510.1039/C5IB00040H25959051 CoxTRBirdDBakerAMBarkerHEHoMWLangGErlerJTLOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasisCancer Res7317211732201310.1158/0008-5472.CAN-12-223323345161 CsiszarKLysyl oxidase: A novel multifunctional amine oxidase familyProg Nucleic Acid Res Mol Biol70132200110.1016/S0079-6603(01)70012-811642359 PayneSLHendrixMJCKirschmannDAParadoxical roles for lysyl oxidases in cancer-a prospectJ Cell Biochem10113381354200710.1002/jcb.2137117471532 Smith-MungoLIKaganHMLysyl oxidase: Properties, regulation and multiple functions in biologyMatrix Biol16387398199810.1016/S0945-053X(98)90012-99524359 KaganHMLiWLysyl oxidase: Properties, specificity, and biological roles inside and outside of the cellJ Cell Biochem88660672200310.1002/jcb.1041312577300 MolnarJFongKSKHeQPHayashiKKimYFongSFFogelgrenBSzauterKMMinkMCsiszarKStructural and functional diversity of lysyl oxidase and the LOX-like proteinsBiochim Biophys Acta1647220224200310.1016/S1570-9639(03)00053-012686136 LuceroHAKaganHMLysyl oxidase: An oxidative enzyme and effector of cell functionCell Mol Life Sci6323042316200610.1007/s00018-006-6149-916909208 BakerAMCoxTRBirdDLangGMurrayGISunXFSouthallSMWilsonJRErlerJTThe role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancerJ Natl Cancer Inst103407424201110.1093/jnci/djq56921282564 ErlerJTBennewithKLNicolauMDornhöferNKongCLeQTChiJTJeffreySSGiacciaAJLysyl oxidase is essential for hypoxia-induced metastasisNature44012221226200610.1038/nature0469516642001 BarkerHEChangJCoxTRLangGBirdDNicolauMEvansHRGartlandAErlerJTLOXL2-mediated matrix remodeling in metastasis and mammary gland involutionCancer Res7115611572201110.1158/0008-5472.CAN-10-286821233336 CoxTRErlerJTRemodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancerDis Model Mech4165178201110.1242/dmm.00407721324931 HasebeTTsudaHHirohashiSShimosatoYIwaiMImotoSMukaiKFibrotic focus in invasive ductal carcinoma: An indicator of high tumor aggressivenessJpn J Cancer Res87385394199610.1111/j.1349-7006.1996.tb00234.x8641970 Van den EyndenGGColpaertCGCouvelardAPezzellaFDirixLYVermeulenPBVan MarckEAHasbeTA fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: Review of the literature and proposal on the criteria of evaluationHistopathology51440451200710.1111/j.1365-2559.2007.02761.x17593207 UehaSShandFHMatsushimaKCellular and molecular mechanisms of chronic inflammation-associated organ fibrosisFront Immunol371201210.3389/fimmu.2012.0007122566952 López-NovoaJMNietoMAInflammation and EMT: An alliance towards organ fibrosis and cancer progressionEMBO Mol Med1303314200910.1002/emmm.20090004320049734 JeongYJBongJGParkSHChoiJIOhHKExpression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancerJ Breast Cancer1496103201110.4048/jbc.2011.14.2.9621847403 RadiskyDCKennyPABissellMJFibrosis and cancer: Do myofibroblasts come also from epithelial cells via EMT?J Cell Biochem101830839200710.1002/jcb.2118617211838 ErtzNCancer: Opening LOX to metastasisNature5224142201510.1038/nature1452926017311 NishiokaTEustaceAWestCLysyl oxidase: From basic science to future cancer treatmentCell Struct Funct377580201210.1247/csf.1101522453058 LeightJLWozniakMAChenSLynchMLChenCSMatrix rigidity regulates a switch between TGF-β 1-induced apoptosis and epithelial-mesenchymal transitionMol Biol Cell23781791201210.1091/mbc.E11-06-053722238361 WynnTABarronLMacrophages: Master regulators of inflammation and fibrosisSemin Liver Dis30245257201010.1055/s-0030-125535420665377 LuzinaIGToddNWIaconoATAtamasSPRoles of T lymphocytes in pulmonary fibrosisJ Leuko Biol83237244200810.1189/jlb.070750417962367 MeldrumKKMetcalfePLeslieJAMisseriRHileKLMeldrumDRTNF-alpha neutralization decreases nuclear factor-kappaB activation and apoptosis during renal obstructionJ Surg Res131181188200610.1016/j.jss.2005.11.581 TashiroKTamadaSKuwabaraNKomiyaTTakekidaKAsaiTIwaoHSugimuraKMatsumuraYTakaokaMAttenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: Possible role of nuclear factor kappaBInt J Mol Med12587592200312964039 KarinMGretenFRNF-kappaB. Linking inflammation and immunity to cancer development and progressionNat Rev Immunol5749759200510.1038/nri170316175180 JulienSPuigICarettiEBonaventureJNellesLvan RoyFDargemontCde HerrerosAGBellacosaALarueLActivation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transitionOncogene2674457456200710.1038/sj.onc.121054617563753 KimHJLitzenburgerBCCuiXDelgadoDAGrabinerBCLinXLewisMTGottardisMMWongTWAttarRMConstitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snailMol Cell Biol2731653175200710.1128/MCB.01315-0617296734 DenkoNCFontanaLAHudsonKMSutphinPDRaychaudhuriSAltmanRGiacciaAJInvestigating hypoxic tumor physiology through gene expression patternsOncogene2259075914200310.1038/sj.onc.120670312947397 HigginsDFKimuraKBernhardtWMShrimankerNAkaiYHohensteinBSaitoYJohnsonRSKretzlerMCohenCDHypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transitionJ Clin Invest11738103820200718037992 NagaiSToiMInterleukin-4 and breast cancerBreast Cancer7181186200010.1007/BF0296745711029795 HasebeTSasakiSImotoSMukiKYokoseTOchiaiAPrognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: A prospective observational studyMod Pathol15502516200210.1038/modpathol.388055512011255 HollosiPYakushijiJKFongKSCsiszarKFongSFLysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells no in normal breast epithelial cellsInt J Cancer125318327200910.1002/ijc.2430819330836 KirschmannDASeftorEAFongSFNievaDRSullivanCMEdwardsEMSommerPCsiszarKHendrixMJA molecular role for lysyl oxidase in breast cancer invasionCancer Res6244784483200212154058 HellmanJJansenMPRuigrok-RitstierKvan StaverenILLookMPMeijer-van GelderMESieuwertsAMKlijnJGSleiJferSFoekensJABernsEMAssociation of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy responseClin Cancer Res1455555564200810.1158/1078-0432.CCR-08-055518765548 PataniNJiangWNewboldRMokbelKPrognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancerJ Carcinog99201010.4103/1477-3163.7250521139993 PeinadoHMoreno-BuenoGHardissonDPérez-GómezESantosVMendiolaMde DiegoJINistalMQuintanillaMPortilloFCanoALysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomasCancer Res6845414550200810.1158/0008-5472.CAN-07-634518559498 McSherryEAMcGoldrickAKayEWHopkinsAMGallagherWMDervanPAFormalin-fixed paraffin-embedded clinical tissues show spurious copy number changes in array-CGH profilesClin Genet72441447200710.1111/j.1399-0004.2007.00882.x17935507

Representative immunohistochemical expression of the members of the lysyl oxidase (LOX) family in invasive breast carcinoma. (A) Negative expression of LOX protein, (B) minimal expression of LOX-like protein (LOXL) 1 protein, (C) moderate expression of LOXL2 protein, (D) marked expression of LOXL3 protein (immunohistochemical staining; magnification, ×200).

Representative histology of fibrotic focus (FF) in invasive breast carcinoma. (A) Representative histology of FF; arrow heads indicate area of FF in invasive breast carcinoma [hematoxylin and eosin (H&E); magnification, ×10], (B) FF with fibrosis grade 1 showing fibroblastic proliferation in stroma with small amount of collagen (H&E; magnification, ×100), (C) FF with fibrosis grade 2 which intermediate between grade 1 and 3 fibrosis (H&E; magnification, ×100), (D) FF with fibrosis grade 3 showing mostly hyalinized collagenous stroma (H&E; magnification, ×100).

Association of fibrotic focus with patient outcome. (A) disease-free survival, and (B) overall survival.

Sequences of primers used in PCR.

Primer name Primer sequence (5′→3′) Orientation
TNF-α CCCTCAACCTCTTCTGGCTC Forward
TNF-α AGGCAGCTCCTACATTGGGT Reverse
IL-1 AAATACCTGTGGCCTTGGGC Forward
IL-1 TTTGGGATCTACACTCTCCAGCT Reverse
IL-2 GCAACTCCTGTCTTGCATTG Forward
IL-2 TGCTTTGACAAAAGGTAATCCA Reverse
IL-4 ATGGGTCTCACCTCCCAACTGC Forward
IL-4 TTCCTGTCGAGCCGTTTCAG Reverse
IL-6 TACCCCCAGGAGAAGATTCC Forward
IL-6 AAAGCTGCGCAGAATGAGAT Reverse
TGF-β CCCAGCATCTGCAAAGCTC Forward
TGF-β GTCAATGTACAGCTGCCGCA Reverse
IFN-γ AGTTATATCTTGGCTTTTCA Forward
IFN-γ ACCGAATAATTAGTCAGCTT Reverse
NF-κB p50 CACCTAGCTGCCAAAGAAGG Forward
NF-κB p50 TCAGCCAGCTGTTTCATGTC Reverse

TNF, tumor necrosis factor; IL, interleukin; TGF, transforming growth factor; IFN, interferon; NF-κB, nuclear factor-κB

Patient characteristics.

Clinicopathologic variables Value
Age (years), mean (range) 51.81±11.29 (24–90)
Menopausal status, n (%)
  Premenopausal 143 (49.14)
  Postmenopausal 148 (50.86)
  Tumor size (cm), mean (range) 2.09±1.80 (0.1–23.0)
Histologic grade, n (%)
  I 64 (22.15)
  II 110 (38.06)
  III 115 (39.79)
Lymph node metastasis, n (%)
  Negative 165 (62.26)
  Positive 100 (37.74)
Stage, n (%)
  I 126 (43.9)
  II 117 (40.77)
  III 36 (12.54)
  IV 8 (2.79)
Lymphovascular invasion, n (%)
  Negative 197 (68.4)
  Positive 91 (31.6)
ER, n (%)
  Negative 102 (35.17)
  Positive 188 (64.83)
PR, n (%)
  Negative 81 (27.93)
  Positive 209 (72.07)
HER2 overexpression, n (%)
  Negative 117 (50.87)
  Positive 114 (49.13)
Ki-67, n (%)
  <14% 129 (58.64)
  ≥14% 91 (41.36)
Molecular subtype, n (%)
  Luminal A 113 (39.65)
  Luminal B 110 (38.6)
  HER2 26 (9.12)
  Basal-like 36 (12.63)
Fibrotic focus, n (%)
  Negative 178 (62.46)
  Positive 107 (37.54)
LOX, n (%)
  Negative 148 (50.86)
  Positive 143 (49.14)
LOXL1, n (%)
  Negative 200 (68.73)
  Positive 91 (31.27)
LOXL2, n (%)
  Negative 176 (60.48)
  Positive 115 (39.52)
LOXL3, n (%)
  Negative 252 (86.6)
  Positive 39 (13.4)
Intratumoral inflammation, n (%)
  Negative 51 (17.53)
  Positive 240 (82.47)
Peritumoral inflammation, n (%)
  Negative 31 (10.65)
  Positive 260 (89.35)

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LOX, lysyl oxidase; LOXL, LOX-like protein.

Association between the fibrotic focus and LOX families.

Fibrotic focus
Variables Negative Positive P-value
LOX, n (%)
  Negative 92 (51.69) 52 (48.6) 0.614
  Positive 86 (48.31) 55 (51.4)
LOXL1, n (%)
  Negative 124 (69.66) 71 (66.36) 0.561
  Positive 54 (30.34) 36 (33.64)
LOXL2, n (%)
  Negative 112 (62.92) 59 (55.14) 0.194
  Positive 66 (37.08) 48 (44.86)
LOXL3, n (%)
  Negative 153 (85.96) 94 (87.85) 0.649
  Positive 25 (14.04) 13 (12.15)

LOX, lysyl oxidase; LOXL, LOX-like protein.

Association of fibrotic focus with clinicopathologic characteristics.

Fibrotic focus
Clinicopathologic variables Negative Positive P-value
Tumor size, n (%)
  <2 cm 120 (67.42) 38 (35.51) <0.001a
  ≥2 cm 58 (32.58) 69 (65.49)
Histologic grade, n (%)
  I 52 (29.38) 10 (9.34) <0.001a
  II 64 (36.16) 45 (42.06)
  III 61 (34.46) 52 (48.60)
Lymph node metastasis, n (%)
  Negative 126 (71.19) 43 (40.19) <0.001a
  Positive 51 (28.81) 64 (59.81)
Stage, n (%)
  I 95 (53.67) 28 (26.67) <0.001a
  II 61 (34.46) 55 (52.38)
  III 16 (9.04) 20 (19.05)
  IV 5 (2.83) 2 (1.90)
Lymphovascular invasion, n (%)
  Negative 136 (76.84) 57 (53.27) <0.001a
  Positive 41 (23.16) 50 (46.73)
ER, n (%)
  Negative 60 (33.90) 39 (36.45) 0.662
  Positive 117 (66.10) 68 (63.55)
PR, n (%)
  Negative 47 (26.55) 31 (28.97) 0.658
  Positive 130 (73.45) 76 (71.03)
HER2 overexpression, n (%)
  Negative 67 (46.21) 46 (57.50) 0.105
  Positive 78 (53.79) 34 (42.50)
Ki-67, n (%)
  <14% 126 (70.79) 70 (65.42) 0.344
  ≥14% 52 (29.21) 37 (34.58)
p53, n (%)
  Negative 49 (27.53) 44 (41.12) 0.018a
  Positive 129 (72.47) 63 (58.88)
Molecular subtype, n (%)
  Luminal A 68 (38.64) 43 (41.75) 0.830
  Luminal B 71 (40.34) 38 (36.89)
  HER2 17 (9.66) 8 (7.77)
  Basal-like 20 (11.36) 14 (13.59)
Intratumoral inflammation, n (%)
  Negative 39 (21.91) 7 (6.54) 0.001a
  Positive 139 (78.09) 100 (93.46)
Peritumoral inflammation, n (%)
  Negative 24 (13.48) 2 (1.87) 0.001a
  Positive 154 (86.52) 105 (98.13)

Denotes statistical significance (P<0.05). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

Multivariate analysis of association between fibrotic focus and clinicopathologic characteristics.

Clinicopathologic variables OR 95% CI for OR P-value
Tumor size, n (%)
  <2 cm 1 – –
  ≥2 cm 4.409 1.726, 11.264 0.002a
Histologic grade, n (%)
  I 1 – –
  II 4.465 1.246, 16.002 0.022a
  III 5.072 1.147, 22.422 0.032a
Lymph node metastasis, n (%)
  Negative 1 – –
  Positive 4.862 1.727, 13.687 0.003a
Stage, n (%)
  I 1 – –
  II .416 0.115, 1.502 0.180
  III .306 0.057, 1.636 0.166
  IV .129 0.012, 1.395 0.092
HER2 overexpression, n (%)
  Negative 1 – –
  Positive .556 0.27, 1.147 0.112
p53, n (%)
  Negative 1 – –
  Positive .456 0.225, 0.926 0.030a
Intratumoral inflammation, n (%)
  Negative 1 – –
  Positive 2.468 0.829, 7.343 0.104
Peritumoral inflammation, n (%)
  Negative 1 – –
  Positive 1.356 0.353, 5.215 0.658

Denotes statistical significance (P<0.05). HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval.

Association of LOX families with clinicopathologic characteristics.

LOX LOXL1 LOXL2 LOXL3
Clinicopathologic variables Positive expression, n (%) P-value Positive expression, n (%) P-value Positive expression, n (%) P-value Positive expression, n (%) P-value
Tumor size, n (%) 0.496 0.674 0.740 0.236
  <2 cm 82 (50.9) 52 (32.3) 65 (40.4) 25 (15.5)
  ≥2 cm 61 (46.9) 39 (30.0) 50 (38.5) 14 (10.8)
Histologic grade, n (%) 0.702 0.549 0.558 0.263
  I 30 (46.9) 18 (27.7) 22 (34.4) 5 (7.8)
  II 52 (47.3) 32 (29.1) 44 (40.0) 15 (13.6)
  III 60 (52.2) 40 (34.8) 49 (42.6) 19 (16.5)
LN metastasis, n (%) 0.596 0.826 0.367 0.805
  Negative 82 (47.7) 54 (31.4) 65 (37.8) 22 (12.8)
  Positive 59 (50.9) 35 (30.2) 50 (43.1) 16 (13.8)
Stage, n (%) 0.916 0.930 0.469 0.752
  I 65 (51.6) 41 (32.5) 50 (39.7) 16 (12.7)
  II 55 (47.0) 37 (31.6) 47 (40.2) 15 (12.8)
  III 18 (50.0) 10 (27.8) 15 (41.7) 7 (19.4)
  IV 4 (50.0) 2 (25.0) 1 (12.5) 1 (12.5)
LVI, n (%) 0.636 0.505 0.262 0.905
  Negative 99 (50.3) 64 (32.5) 83 (42.1) 27 (13.7)
  Positive 43 (47.3) 26 (28.6) 32 (35.2) 12 (13.2)
ER, n (%) 0.469 0.374 0.465 0.001a
  Negative 47 (46.1) 35 (34.7) 43 (42.2) 23 (22.5)
  Positive 95 (50.5) 55 (29.3) 71 (37.8) 16 (8.5)
PR, n (%) 0.663 0.969 0.622 <0.001a
  Negative 38 (46.9) 25 (30.9) 30 (37.0) 20 (24.7)
  Positive 104 (49.8) 65 (31.1) 84 (40.2) 19 (9.1)
HER2 overexpression, n (%) 0.954 0.323 0.216 0.101
  Negative 56 (47.9) 32 (27.4) 42 (35.9) 11 (9.4)
  Positive 55 (48.2) 38 (33.3) 50 (43.9) 19 (16.7)
Ki-67, n (%) 0.182 0.334 0.992 0.503
  <14% 93 (46.5) 59 (29.5) 79 (39.5) 25 (12.5)
  ≥14% 50 (54.9) 32 (35.2) 36 (39.6) 14 (15.4)
Molecular subtype, n (%) 0.680 0.467 0.671 <0.001a
  Luminal A 56 (49.6) 30 (26.5) 44 (38.9) 13 (11.5)
  Luminal B 56 (50.9) 38 (34.5) 46 (41.8) 8 (7.3)
  HER2 10 (38.5) 10 (38.5) 11 (42.3) 11 (42.3)
  Basal-like 19 (52.8) 10 (27.8) 11 (30.6) 7 (19.4)
IT, n (%) <0.001a 0.021a 0.004a 0.199
  Negative 11 (21.5) 9 (17.6) 11 (21.6) 4 (7.8)
  Positive 132 (55.0) 82 (34.2) 104 (43.3) 35 (14.6)
PT, n (%) <0.001a 0.130 0.041a 0.229
  Negative 6 (19.4) 6 (19.4) 7 (22.6) 2 (6.5)
  Positive 137 (52.7) 85 (32.7) 108 (41.5) 37 (14.2)

Denotes statistical significance (P<0.05). LN, lymph node; LVI, lymphovascular invasion; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; IT, intratumoral inflammation; PT, peritumoral inflammation; LOX, lysyl oxidase; LOXL, LOX-like protein.

Association of fibrotic focus and LOX families with inflammatory markers.

Fibrotic focus LOX LOXL1 LOXL2 LOXL3
Inflammatory markers Negative Positive P-value Negative Positive P-value Negative Positive P-value Negative Positive P-value Negative Positive P-value
TNF-α, n (%) 0.458 0.712 0.703 0.817 0.627
  Negative   5 (27.8) 6 (40.0) 4 (26.7)   6 (35.3)   6 (28.6) 4 (36.4)   7 (29.2) 3 (33.3)   8 (28.6) 2 (40.0)
  Positive 13 (72.2) 9 (60.0) 11 (73.3) 11 (64.7) 15 (71.4) 7 (63.6) 17 (70.8) 6 (66.7) 20 (71.4) 3 (60.0)
IL-4, n (%) 0.898 0.982 0.019a 0.259 0.175
  Negative 10 (55.6) 8 (53.3) 7 (46.7) 8 (47.1) 13 (61.9) 2 (18.2) 10 (41.7) 6 (66.7) 12 (42.9) 4 (80.0)
  Positive   8 (44.4) 7 (46.7) 8 (53.3) 9 (52.9)   8 (38.1) 9 (81.8) 14 (58.3) 3 (33.3) 16 (57.1) 1 (20.0)
NF-κB p50, n (%) 0.354 0.469 0.344 0.273 0.152
  Negative 1 (5.6) 0 (0.0) 1 (6.7) 0 (0.0) 0 (0.0) 1 (9.1) 0 (0.0) 1 (11.1) 0 (0.0) 1 (20.0)
  Positive 17 (94.4) 15 (100.0) 14 (93.3) 17 (100.0) 21 (100.0) 10 (90.9) 24 (100.0) 8 (88.9) 28 (100.0) 4 (80.0)
CD4+ T cell, mean (n) 34.7 24.6 0.408 24.3   36.8 0.248 28.3 34.0 0.627   31.5 32.9 0.907 28.3   34.0 0.627
CD8+ T cell, mean (n) 105.3 103.4 0.944 79.0 132.8 0.030c 95.0 123.2 0.299 102.7 106.4 0.891 95.0 120.2 0.299
CD68+ cell 31.9 30.0 0.801   29.14   33.8 0.515 31.7 30.4 0.868   31.9 30.1 0.814 31.4   24.7 0.868
(Macrophage), mean (n)

Denotes statistical significance (P<0.05) LOX, lysyl oxidase; LOXL, lysyl oxidase-like protein; TNF, tumor necrosis factor; IL, interleukin; NF-κB, nuclear factor-κB.